Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
NYSE:JNJ
Price:
148.58 USD
-0.46%
Market Closed
Updated:
May 7, 2024
Johnson & Johnson
Revenue
|
Johnson & Johnson
Revenue Peer Comparison
Comparables:
BMY
PFE
MRK
ZTS
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$8.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
Johnson & Johnson
Revenue Breakdown
Breakdown by Geography
Johnson & Johnson
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
United States:
46.4B
USD
|
|
Europe:
20.4B
USD
|
|
Asia-Pacific, Africa:
13.8B
USD
|
|
Western Hemisphere, Excluding U.s:
4.5B
USD
|
Breakdown by Segments
Johnson & Johnson
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
Innovative Medicine:
54.8B
USD
|
|
Medtech:
30.4B
USD
|
|
Stelara:
10.9B
USD
|
|
Darzalex:
9.7B
USD
|
|
General:
5.4B
USD
|
|
Electrophysiology:
4.7B
USD
|
|
Advanced:
4.7B
USD
|
|
Invega Sustenna/Xeplion/Trinza/Trevicta:
4.1B
USD
|
|
Contact Lenses/Other:
3.7B
USD
|
|
Imbruvica:
3.3B
USD
|
|
Tremfya:
3.1B
USD
|
|
Trauma:
3B
USD
|
|
Spine,Sports & Other:
2.9B
USD
|
|
Erleada:
2.4B
USD
|
|
Xarelto:
2.4B
USD
|
|
Simponi/Simponi Aria:
2.2B
USD
|
|
Opsumit:
2B
USD
|
|
Prezista/Prezcobix/Rezolsta/Symtuza:
1.9B
USD
|
|
Remicade:
1.8B
USD
|
|
Uptravi:
1.6B
USD
|
|
Hips:
1.6B
USD
|
|
Other Neuroscience:
1.6B
USD
|
|
Knees:
1.5B
USD
|
|
Surgical:
1.4B
USD
|
|
Abiomed:
1.3B
USD
|
|
Other:
1.3B
USD
|
|
Edurant/Rilpivirine:
1.2B
USD
|
|
Covid-19:
1.1B
USD
|
|
Zytiga/Abiraterone Acetate:
887m
USD
|
|
Other Oncology:
879m
USD
|
|
Concerta/Methylphenidate:
783m
USD
|
|
Risperdal Consta:
689m
USD
|
|
Carvykti:
500m
USD
|
|
Other Interventional Solutions:
356m
USD
|
|
Other Infectious Diseases:
297m
USD
|
|
Other Immunology:
11m
USD
|
See Also
What is Johnson & Johnson's Revenue?
Revenue
85.6B
USD
85.6B
USD
Based on the financial report for Mar 31, 2024, Johnson & Johnson's Revenue amounts to 85.6B USD.
What is Johnson & Johnson's Revenue growth rate?
Revenue CAGR 10Y
2%
2%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Johnson & Johnson have been 1% over the past three years , 1% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
